The present invention relates to the fields of metal-organic framework formation (MOF), mixed-matrix membrane (MMM) fabrication and membrane-based gas and liquid separation. More particularly, the present invention relates to a one step method for the scalable formation of high-performance asymmetric MMMs for membrane-based gas separation.
Membrane-based gas separation is an attractive energy-efficient alternative to the conventional thermally-driven technologies (1, 2). Several polymer membranes have successfully been applied for the commercial separations of light gases (3). The separation performances of the polymer membranes are, however, limited by a trade-off between permeability and selectivity (4), thereby hindering their applications for rapidly growing diverse gas separation markets such as olefin/paraffin separations (3, 5). While current MMMs have shown improved gas separation performances compared to their polymer counterparts, the commercial applications of the MMMs have been substantially hampered by several engineering and scientific challenges (6-8). There have been tremendous efforts to address the scientific challenges including poor filler-polymer interfacial interactions and filler agglomeration (9). On the other hand, much less attention has been given to the engineering challenges for economically manufacturing defect-free MMMs in a scalable geometry (i.e., asymmetric microstructures with thin selective mixed-matrix layers) (6). The engineering challenges result mostly from the conventional physical blending based MMM processing, which turns out extremely difficult to rapidly prepare asymmetric membranes with thin selective mixed-matrix layers. It is, therefore, highly desirable to develop a fundamentally new MMM fabrication strategy that can overcome both of the scientific and engineering challenges.
In-situ MMM fabrication is an emerging strategy that might potentially overcome the limitations of the conventional blending methods. Marti et al. (10) demonstrated a simple one-step fabrication of Matrimid®/UiO-66 MMMs using in-situ filler formation in a polymer solution containing UiO-66 precursors. Despite facile MMM formation, the membranes showed limited filler loadings due to the particle agglomeration, exhibiting not much improvement in their gas separation performances as compared to those conventionally prepared (10). Recently, a novel scalable in-situ MMM fabrication strategy, termed as polymer-modification-enabled metal-organic framework formation (PMMOF) (11) was reported. The PMMOF decouples filler incorporation from membrane formation by in-situ forming MOF fillers in preformed polymer films, thereby enabling the transformation of polymer membranes to MMMs (11). Using the PMMOF, the first MMM modules were made of ZIF-8-containing asymmetric MMM hollow fibers (12). Although the PMMOF process effectively suppressed the issues of conventional blending-based MMMs, the process involves multiple steps, likely adding the manufacturing cost. More importantly, the PMMOF can be applied only to polyimide-based polymers, compromising its versatility.
Thus, there is a need in the art for new methods of preparing high-performance mixed-matrix membranes. The prior art is deficient in a one-step scalable in-situ asymmetric MMM fabrication process. Particularly, the prior art is deficient in an in-situ fabrication process that synchronizes metal-organic framework (MOF) formation with polymer phase-inversion. The present invention fulfills this long-standing need and desire in the art.
The present invention is directed to a one-step method for fabricating an asymmetric mixed-matrix membrane. In the method an asymmetric polymer film is formed simultaneously with forming metal organic framework (MOF) filler particles therein.
The present invention also is directed to an asymmetric mixed-matrix membrane fabricated by the method described herein.
The present invention is directed further to a method for separating a mixture of gases or of liquids comprising flowing the mixture through the asymmetric mixed-matrix membrane described herein
The present invention is directed further still to an asymmetric mixed-matrix membrane fabrication process. The fabrication process comprises a single step of transforming, via phase inversion at room temperature to about 40° C., a metal precursor containing liquid polyimide solution into which an imidazole diffuses during solidification of the polyimide solution to an asymmetric polymer film simultaneously as the metal precursor reacts in situ with the imidazole to form metal-imidazolate framework filler particles therein.
These and other features, aspects, and advantages of the embodiments of the present disclosure will become better understood when the following detailed description is read with reference to the accompanying drawings.
So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.
The articles “a” and “an” when used in conjunction with the term “comprising” in the claims and/or the specification, may refer to “one”, but it is also consistent with the meaning of “one or more”, “at least one”, and “one or more than one”. Some embodiments of the invention may consist of or consist essentially of one or more elements, components, method steps, and/or methods of the invention. It is contemplated that any composition, component or method described herein can be implemented with respect to any other composition, component or method described herein.
The term “or” in the claims refers to “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or”.
The terms “comprise” and “comprising” are used in the inclusive, open sense, meaning that additional elements may be included.
The term “including” is used herein to mean “including, but not limited to”. “Including” and “including but not limited to” are used interchangeably.
As used herein, the term “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term “about” generally refers to a range of numerical values (e.g., +/−5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure. For example, about 50 wt % encompasses 45 wt % to 55 wt % and about 40° C. encompasses 36° C. to about 44° C.
As used herein, the term “room temperature” refers to a temperature of about 20° C. to about 26° C.
In one embodiment of this invention, there is provided a one-step method for fabricating an asymmetric mixed-matrix membrane, comprising forming an asymmetric polymer film simultaneously with forming metal organic framework (MOF) filler particles therein.
In an aspect of this embodiment forming the asymmetric polymer film may comprise transforming a liquid polymer solution containing a metal precursor in the presence of a ligand precursor to a solid polymer film with an asymmetric structure via phase inversion. In this aspect forming the MOF filler particles may comprise diffusing the ligand precursor into the polymer solution as it solidifies to react in situ with the metal precursor to form the MOF filler particles therein. Particularly, forming the MOF filler particles may occur at room temperature to less than 100° C.
In this aspect the polymer in the liquid polymer solution may be a polyimide polymer. Also, the metal precursor may be a nitrate, acetate, nitride, or sulfate of the metal or a chloride salt solution of zinc, cobalt, magnesium, manganese, iron, nickel, copper, zirconium, or cadmium, or a combination thereof. In addition the ligand precursor may be an organic linker. Particularly, the organic linker may be imidazole, 2-methyl imidazole, 2-ethylimidazole, 2-nitroimidazole, benzimidazole, 6-nitrobenzimidazole, 1-hexyl-3-methylimidazolium or purine or a combination thereof. Furthermore, the MOF filler particles may be zeolitic-imidazolate-framework filler particles.
In another embodiment of the present invention there is provided an asymmetric mixed-matrix membrane fabricated by the method as described supra. In an aspect of this embodiment an asymmetric polymer film may be formed with a skin layer on top of a bottom porous layer and a plurality of zeolitic-imidazolate-framework (ZIF) filler particles dispersed within the polymer film. Particularly, the skin layer may comprise a plurality of intermediate layers with a majority of the plurality of the zeolitic-imidazolate-framework filler particles dispersed therein. In this aspect the majority of the zeolitic-imidazolate-framework filler particles may comprise about 50 wt % of the skin layer. Also in this aspect the zeolitic-imidazolate-framework filler particles may be less than 5 nm to about 10 nm in size. In this embodiment and aspects thereof the asymmetric mixed-matrix membrane may be a 6FDA-DAM/ZIF-8 asymmetric mixed-matrix membrane.
In yet another embodiment of the present invention there is provided a method for separating a mixture of gases or of liquids comprising flowing the mixture through the asymmetric mixed-matrix membrane, as described supra. In one aspect of this embodiment the mixture of gases may be a binary gas mixture. Particularly, the binary gas mixture may be a propylene/propane gas mixture. In another aspect of this embodiment the mixture of liquids may be a mixture of organic liquids or a mixture of at least one organic liquid and water.
In yet another embodiment of the present invention there is provided an asymmetric mixed-matrix membrane fabrication process, comprising transforming, via phase inversion at room temperature to about 40° C., a metal precursor containing liquid polyimide solution into which an imidazole diffuses during solidification of the polyimide solution to an asymmetric polymer film simultaneously as the metal precursor reacts in situ with the imidazole to form metal-imidazolate framework filler particles therein. In this embodiment the metal precursor may be a zinc nitrate. Also in this embodiment the method 6FDA-DAM/ZIF-8 asymmetric mixed-matrix membrane may be fabricated.
The present invention provides a one-step method to fabricate asymmetric polymer membranes and films, such as asymmetric mixed-matrix membrane, and the mixed-matrix membranes fabricated thereby. The one-step method is scalable. The method is a phase-inversion in sync with metal-organic framework formation (PIMOF) process. The key to the one-step method is the simultaneity of dry-jet/wet-quenching induced polymer phase inversion and in-situ synthesis of metal-organic framework (MOF) crystals. Generally, a casted polymer solution containing a metal precursor is immersed in a coagulation bath containing a ligand precursor whereby diffusion of the metal precursor and the ligand precursor form metal-organic framework particles within the polymer. A non-limiting example of an asymmetric mixed-matrix membrane is a 6FDA-DAM/ZIF-8 mixed matrix membrane.
In the in-situ nucleation and growth of the MOF particle fillers occurs instantly by rapid reactions. Moreover, increasing the ligand precursor concentration in the coagulation bath increases the performance of the asymmetric polymer membranes and films. Correspondingly, increasing the temperature of the coagulation bath results in a thinner separation layer due to higher phase inversion rate. The temperature of the coagulation bath may be room temperature to less than 100° C., particularly, about 40° C. to less than 60° C.
The polymer may be any polymer, for example, a polyimide polymer. Non-limiting examples of a polymer are (4,4-(Hexafluoroisopropylidene)diphthalic anhydride-2,4,6-trimethyl-1,3-phenylene diamine (6FDA-DAM), pyromellitic dianhydrides oxidianiline (PMDA-ODA), 3,3-4,4-benzophenone tetracarboxylic dianhydride diaminophenylindane (BTDA-DAPI). Representative examples of the metal precursor are, but are not limited to, nitrates, acetates, nitrides, sulfates or chloride salt solutions of zinc, cobalt, magnesium, manganese, iron, nickel, copper, zirconium, or cadmium, or a combination thereof. The ligand precursor may be any organic ligand useful in a metal organic framework ligands. The organic ligand may be an imidazolate-based ligand. Representative examples of the ligand precursor are, but are not limited to, imidazole, 2-methyl imidazole, 2-ethylimidazole, 2-nitroimidazole, benzimidazole, 6-nitrobenzimidazole, 1-hexyl-3-methylimidazolium or purine, or a combination thereof.
The MOF particle fillers may be nanoparticles. The MOF particle fillers may be zeolitic-imidazolate-framework particles. The zeolitic-imidazolate-framework is, but is not limited to, a mixed-metal zeolitic-imidazolate-framework, a mixed-linker zeolitic-imidazolate-framework, or a mixed-metal/mixed-linker zeolitic-imidazolate-framework. A representative example of a zeolitic-imidazolate-framework is ZIF-8 MOF.
The asymmetric mixed-metal membranes fabricated by the one-step method or process are used to separate fluid mixtures, for example, mixtures of gases and of liquids by flowing the mixture therethrough. The mixture of gases may be a mixture of at least two gases. A representative example is a binary gas mixture, for example, a mixture of C3 gases, such as a propylene/propane gas mixture. The mixture of liquids may be a mixture of at least two organic liquids and water.
The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
4,4-(Hexafluoroisopropylidene) diphthalic anhydride 2,4,6-trimethyl-1,3-phenylenediamine (6FDA-DAM) (Mw: 148k, PDI: 2.14) was purchased from Akron Polymer Systems Inc. 1-methyl-2-pyrrolidone (NMP, C5H9NO, >99.0%, Sigma-Aldrich), tetrahydrofuran (THF, C4H80, >99.0%, Alfa Aesar), methanol (MeOH, CH3OH, >99.8%, VWR International), ethanol (EtOH, C2H5OH, 94-96%, Alfa Aesar), zinc nitrate hexahydrate (ZnN, Zn(NO3)2.6H2O, 98%, Sigma-Aldrich), and 2-methylimidazole (Hmlm, C4H6N2, 99%, Sigma-Aldrich) were used. All chemicals were used as received without further purification.
Zn solutions of different concentrations were prepared by dissolving ZnN of 0.1 mmol, 0.3 mmol, and 0.6 mmol in 0.5 ml DI water. Likewise, ligand solutions of different concentrations were prepared by dissolving Hmlm of 5 mmol, 10 mmol, and 20 mmol in 10 ml DI water. A Zn solution was dropped into a ligand solution. Immediately, the mixture solution turned white and the reaction proceeded for 5 min at room temperature. Precipitates were collected by centrifuging the suspension for 10 min. Afterward, the precipitates were washed with MeOH and centrifuged for 15 min. The acquired samples were dried at 60° C. overnight.
A polymer solution was prepared by dissolving 15 wt % of 6FDA-DAM in 40.7 w % NMP and 20.3 wt % THF, followed by addition of non-solvent additives of 6 wt % ZnN and 18 wt % EtOH. The solution was shaken on a lab shaker overnight at room temperature until it became homogeneous. The homogenous polymer solution was then casted with thickness of ˜470 μm on a polypropylene (PP) filter (Whatman, 7002-0290) at room temperature using a casting knife. The casted nascent polymer film was immersed immediately into an aqueous coagulation bath containing Hmlm with varying concentrations (0.0 M, 0.5 M, 1.0 M, 1.5 M, and 2.0 M) in 150 ml DI water. The resulting membrane sample was kept into the coagulation bath for 1 hr and moved to a MeOH solution for solvent exchange. After 1 hr in the MeOH solution, the sample was slowly dried under a nearly saturated environment with MeOH for 48 hrs. The resulting membrane was measured at ca. 130±10 μm in thickness and stored in a petri dish for characterization and testing. For a comparison purpose, a conventional MMM with ca. 20 wt % ZIF-8 loading was prepared using a priming and blending method. ZIF-8 particles were prepared by following a procedure described elsewhere (1). A ZIF-8/solvent suspension was prepared by dispersing the ZIF-8 particles in THF in a sonication bath. Afterward, a small amount of 6FDA-DAM (10 wt % of the total polymer in MMMs) was added into the ZIF-8 suspension and stirred for 6 hours. The remaining polymer was added into the suspension and further stirred overnight on a lab shaker. Once the mixture solution became homogeneous, it was casted on a glass plate and covered with aluminum foil. The solvent was slowly evaporated at room temperature for 2 days. The membrane was determined ca. 280 μm thick.
Scanning electron microscope (SEM) images were taken using a JEOL JSM-7500F at acceleration voltage of 5 keV and working distance of 15 mm. Transmission electron microscopy (TEM) analysis was conducted using a FEI Tecnai G2 F20 Super-Twin FE-TEM operating at 120 keV. TEM samples were prepared using a Tescan LYRA-3 Model GMH dual-beam FIB instrument. X-ray diffraction (XRD) patterns were collected using a Miniflex II diffractometer (Rigaku) with Cu-Kα radiation (λ=1.5406 Å) in the 2θ range of 5-40 o. A Nicolet iS5 spectrophotometer equipped with iD7 ATR (Thermo Scientific) was used to obtain attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectra at a resolution of 5 cm-1 with 16 scans in the span of 4000-400 cm-1. Thermogravimetric analysis (TGA) was performed using Q50 (TA instruments) in the temperature range of 25° C. to 800° C. at the heating rate of 10° C. min-1 under air flow of 60 cm3 min-1. N2 adsorption isotherms were taken using ASAP 2020 plus (Micromeritics) at 77 K
An equimolar binary propylene/propane separation performance of the membranes were performed using the Wicke-Kallenbach technique at room temperature under atmospheric pressure. A feed gas mixture was provided at the total flow rate of 100 cm3 min-1. Argon sweeping gas was flowed onto the permeate side at the same flow rate of the feed gas. A membrane was placed in a custom-made permeation cell and sealed with rubber rings. The composition of the permeate was detected using a gas chromatography (GC 7890A, Agilent) equipped with a flame ionized detector (FID) and a HP-plot Q column.
The proposed novel MMM fabrication strategy, phase-inversion in sync with metal-organic framework formation (PIMOF), is based on the in-situ formation of ZIF-8 nanoparticles concurring with the formation of an asymmetric polymer film by phase inversion. It is noted that the phase inversion technique has been widely used to prepare commercial asymmetric polymer membranes (both flat and hollow fibers) (13, 14).
As the casted nascent polymer film is immersed into a coagulation bath containing Hmlm ligands, phase inversion is induced by liquid-liquid demixing (
The composition of the polymer solution is of critical importance in order to obtain a defect-free dense skin layer on top of a porous layer in an asymmetric membrane (15, 17). Since the polymer solution must be in a single phase, the ternary polymer/solvent/non-solvent system was carefully investigated by varying the composition of the solution, thereby determining a ternary phase diagram. As shown in the phase diagram (
Due to the counter diffusion of zinc ions in the polymer solution film and Hmlm in the coagulation bath, ZIF-8 filler particles form in-situ inside the polymer film in sync with polymer phase-inversion.
Formation of ZIF-8 Particles Inside the Polymer in Sync with Polymer Phase Inversion
The overall amounts of ZIF-8 fillers in the PIMOF MMMs were determined using thermal gravimetric analysis (TGA) (
The highest total ZIF-8 loading was estimated ca. 15 wt %, which was achieved at 2.0 M of the linker concentration and 40° C. of the bath temperature. It is noted that the total ZIF-8 loading includes filler particles formed in the skin layer as well as those in the bottom porous layer. As shown in
To investigate the microstructure of the ZIF-8-containing skin layers, TEM and STEM analyses were performed on the PIMOF MMM prepared in a coagulation bath containing 2.0 M of Hmlm at 40° C. (hereafter, PIMOF MMM (2.0 M, 40° C.).
As can be seen in the figures, there are many bright and dark spots in the STEM and the TEM images, respectively, uniform in size of ca. 5 nm, which are assigned most likely to ZIF-8 filler nanoparticles. In addition, one can observe even brighter (STEM) and darker (TEM) spots irregular in size that are larger than the nanosized spots.
The increase in the C3H6 permeance was somewhat modest as compared to that in the separation factor, which was attributed to the similar thickness of the skin layer (SEM images in
When the coagulation bath temperature was raised to 40° C., the resulting PIMOF MMMs showed the dramatically enhanced C3 separation performance (
As shown in
The following references are cited herein.
This non-provisional patent application claims benefit of priority under 35 U.S.C. § 119(e) of provisional application U.S. Ser. No. 63/173,787, filed Apr. 12, 2021, the entirety of which is hereby incorporated by reference.
This invention was made with government support under Grant Number CBET-1929596 and Grant Number DBI-0116835 awarded by the National Science Foundation. The government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
63173787 | Apr 2021 | US |